Citigroup’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-248,768
| Closed | -$42.8M | – | 6245 |
|
|
2021
Q3 | $42.8M | Buy |
248,768
+198,437
| +394% | +$26M | 0.03% | 604 |
|
|
2021
Q2 | $6.32M | Buy |
50,331
+4,354
| +9% | +$549K | ﹤0.01% | 1720 |
|
|
2021
Q1 | $6.24M | Buy |
45,977
+18,714
| +69% | +$2.42M | ﹤0.01% | 1647 |
|
|
2020
Q4 | $3.49M | Sell |
27,263
-27,990
| -51% | -$3.28M | ﹤0.01% | 2353 |
|
|
2020
Q3 | $6.22M | Sell |
55,253
-39,012
| -41% | -$3.88M | ﹤0.01% | 1754 |
|
|
2020
Q2 | $8.98M | Buy |
94,265
+58,924
| +167% | +$5.68M | 0.01% | 1385 |
|
|
2020
Q1 | $3.18M | Sell |
35,341
-8,530
| -19% | -$663K | ﹤0.01% | 2060 |
|
|
2019
Q4 | $2.33M | Sell |
43,871
-9,649
| -18% | -$440K | ﹤0.01% | 2817 |
|
|
2019
Q3 | $2.12M | Sell |
53,520
-19,510
| -27% | -$846K | ﹤0.01% | 2807 |
|
|
2019
Q2 | $3M | Buy |
73,030
+57,029
| +356% | +$2.36M | ﹤0.01% | 2399 |
|
|
2019
Q1 | $745K | Sell |
16,001
-120,334
| -88% | -$5.28M | ﹤0.01% | 3736 |
|
|
2018
Q4 | $5.94M | Buy |
136,335
+128,787
| +1,706% | +$6.43M | 0.01% | 1677 |
|
|
2018
Q3 | $432K | Sell |
7,548
-11,969
| -61% | -$588K | ﹤0.01% | 4459 |
|
|
2018
Q2 | $947K | Sell |
19,517
-19,292
| -50% | -$703K | ﹤0.01% | 3417 |
|
|
2018
Q1 | $1.52M | Sell |
38,809
-12,828
| -25% | -$545K | ﹤0.01% | 2857 |
|
|
2017
Q4 | $2.19M | Sell |
51,637
-806,656
| -94% | -$30.3M | ﹤0.01% | 2584 |
|
|
2017
Q3 | $32M | Buy |
858,293
+830,721
| +3,013% | +$28.8M | 0.03% | 574 |
|
|
2017
Q2 | $838K | Buy |
27,572
+7,102
| +35% | +$206K | ﹤0.01% | 3498 |
|
|
2017
Q1 | $541K | Sell |
20,470
-66,014
| -76% | -$1.74M | ﹤0.01% | 3807 |
|
|
2016
Q4 | $2.21M | Buy |
86,484
+74,987
| +652% | +$2.38M | ﹤0.01% | 2824 |
|
|
2016
Q3 | $416K | Buy |
11,497
+1,783
| +18% | +$59.1K | ﹤0.01% | 4063 |
|
|
2016
Q2 | $330K | Sell |
9,714
-11,777
| -55% | -$383K | ﹤0.01% | 4050 |
|
|
2016
Q1 | $568K | Buy |
21,491
+11,326
| +111% | +$329K | ﹤0.01% | 3988 |
|
|
2015
Q4 | $496K | Buy |
10,165
+5,346
| +111% | +$192K | ﹤0.01% | 3871 |
|
|
2015
Q3 | $120K | Sell |
4,819
-5,498
| -53% | -$165K | ﹤0.01% | 4852 |
|
|
2015
Q2 | $326K | Sell |
10,317
-2,496
| -19% | -$80.5K | ﹤0.01% | 4069 |
|
|
2015
Q1 | $488K | Sell |
12,813
-3,564
| -22% | -$142K | ﹤0.01% | 3767 |
|
|
2014
Q4 | $638K | Buy |
16,377
+11,577
| +241% | +$403K | ﹤0.01% | 3622 |
|
|
2014
Q3 | $145K | Buy |
4,800
+1,285
| +37% | +$36.2K | ﹤0.01% | 4454 |
|
|
2014
Q2 | $119K | Sell |
3,515
-858
| -20% | -$28.7K | ﹤0.01% | 4551 |
|
|
2014
Q1 | $151K | Sell |
4,373
-836
| -16% | -$37.7K | ﹤0.01% | 4618 |
|
|
2013
Q4 | $207K | Buy |
+5,209
| New | +$126K | ﹤0.01% | 4629 |
|
Citigroup's XLRN Position: Q4 2021 in Review
Citigroup sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 248,768 shares — an estimated $42.8M sold.
Citigroup first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $42.8M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Citigroup reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Citigroup sold 248,768 Acceleron Pharma shares in Q4 2021, an estimated $42.8M.
- Citigroup first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Citigroup's Acceleron Pharma position peaked at $42.8M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Citigroup's 13F filing for Q4 2021, filed 10 Feb 2022.